TL;DR: The Centers for Medicare & Medicaid Services modified NCD 160 governing cardiac pacemaker evaluation services, effective March 7, 2026. Here's what billing teams need to do.
CMS updated National Coverage Determination 160 — the policy governing Medicare coverage of post-implant follow-up and evaluation services for implanted cardiac pacemakers. The modification affects how Medicare Administrative Contractors (MACs) identify, process, and apply frequency guidelines to pacemaker monitoring claims, with particular focus on lithium battery-powered units. This policy applies to outpatient hospital diagnostic services and falls under the "Diagnostic Tests (other)" benefit category. No specific CPT or HCPCS codes are listed in the current policy document — more on what that means for your billing team below.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Cardiac Pacemaker Evaluation Services |
| Policy Code | NCD 160 |
| Change Type | Modified |
| Effective Date | 2026-03-07 |
| Impact Level | Medium |
| Specialties Affected | Cardiology, Electrophysiology, Outpatient Hospital Billing, Cardiac Device Clinics, Remote Monitoring Services |
| Key Action | Review pacemaker monitoring frequency documentation and physician prescription requirements before March 7, 2026 |
CMS Cardiac Pacemaker Evaluation Coverage Criteria and Medical Necessity Requirements 2026
Medicare covers post-implant follow-up and evaluation services for implanted cardiac pacemakers — but coverage is conditional, and the medical necessity standard here is more nuanced than most billing teams treat it.
The first thing to internalize: NCD 160 is explicitly limited to lithium battery-powered pacemakers. Mercury-zinc battery-powered units are no longer manufactured and have virtually all been replaced, but if your MAC is still receiving claims for mercury-zinc monitoring, the 1980 guidelines continue to apply until those units are replaced. This is a narrow carve-out, but if you're working with an older patient population, confirm battery type in the medical record before billing.
Coverage extends to two pacemaker types: single-chamber devices (sensing and pacing the ventricles) and dual-chamber devices (sensing and pacing both the atria and ventricles). These two types carry different monitoring frequency expectations over the device lifecycle — and that distinction drives whether a claim holds up or gets flagged as excessive. Don't treat them the same in your documentation.
Here's the twist that trips up billing teams regularly: a dual-chamber unit programmed to pace only the ventricles — whether at implant or reprogrammed afterward — must be treated as a single-chamber pacemaker for purposes of applying the CMS screening and frequency guidelines. If you're billing dual-chamber monitoring rates on a device that's been reprogrammed for ventricular-only pacing, you're exposed. Check the programming documentation, not just the implant record.
On prior authorization: NCD 160 does not specify a prior authorization requirement. However, the policy does require a physician prescription for monitoring — and that prescription must be periodically renewed, at minimum annually. For monitoring performed by entities other than the treating physician (commercial monitoring services, hospital outpatient departments), this prescription requirement is non-negotiable. Missing or expired prescriptions are a direct path to claim denial under this coverage policy.
The medical necessity determination for monitoring frequency belongs to the treating physician. CMS is explicit that individual patient condition and circumstances may change, requiring adjustments to how often monitoring is appropriate. MACs are expected to apply frequency guidelines using their own data and experience — meaning there's deliberate flexibility built in, but that flexibility cuts both ways. Claims above typical frequency thresholds will draw scrutiny. Document the clinical rationale, not just the fact that monitoring occurred.
Because there are over 200 pacemaker models in active use at any given time, plus a wide range of underlying patient conditions, CMS acknowledges this is inherently complex. The guidance to MACs is to develop local frequency guidelines informed by this NCD. That means reimbursement patterns may vary by MAC jurisdiction — what clears without issue in one region may trigger development in another.
CMS Cardiac Pacemaker Evaluation Exclusions and Non-Covered Indications
NCD 160 does not enumerate a formal list of experimental or investigational indications. But the policy creates functional non-coverage through its frequency guidelines framework.
Monitoring claims that exceed what the patient's physician has prescribed — or what the MAC's local frequency guidelines allow — will not be covered. The frequency standard is not a soft suggestion. Claims that exceed it without documented clinical justification are effectively non-covered, even if the service itself is a covered type of monitoring.
Monitoring performed without a current physician prescription is also non-covered for patients managed by third-party monitoring services or hospital outpatient departments. An expired annual prescription creates the same billing problem as no prescription at all.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Post-implant follow-up for lithium battery single-chamber pacemaker | Covered | Not specified in policy | Frequency must align with MAC guidelines and physician prescription |
| Post-implant follow-up for lithium battery dual-chamber pacemaker | Covered | Not specified in policy | Different monitoring frequency schedule than single-chamber |
| Dual-chamber unit programmed for ventricular-only pacing | Covered (as single-chamber) | Not specified in policy | Must be billed and monitored under single-chamber guidelines |
| Transtelephonic monitoring | Covered | Not specified in policy | Frequency counted alongside in-clinic visits when evaluating reasonableness |
| In-clinic monitoring | Covered | Not specified in policy | Combined frequency with transtelephonic monitoring assessed together |
| Monitoring of mercury-zinc battery pacemakers | Covered (legacy) | Not specified in policy | Apply 1980 guidelines; extremely rare at this point |
| Monitoring without current physician prescription (third-party monitoring) | Not Covered | Not specified in policy | Prescription must be renewed at least annually |
| Monitoring exceeding prescribed or MAC-guideline frequency | Not Covered | Not specified in policy | Clinical documentation required to support above-guideline frequency |
CMS Cardiac Pacemaker Evaluation Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Audit your dual-chamber claims against current programming records before March 7, 2026. If a dual-chamber device has been reprogrammed for ventricular-only pacing, your billing and documentation must reflect single-chamber status. Pull the most recent device interrogation reports — not just the implant operative note — to confirm current programming. |
| 2 | Verify physician prescriptions are on file and current for every patient managed by a third-party monitoring service or hospital outpatient department. Prescriptions must be renewed at minimum annually. Run a report now for any prescriptions dated before March 7, 2025 — those are expired or expiring and need renewal before the effective date. |
| 3 | Document combined monitoring frequency across all settings. If a patient receives both in-clinic and transtelephonic (remote) monitoring, your MAC will aggregate both when assessing frequency reasonableness. Track cumulative monitoring events per patient, and make sure the physician's prescription reflects the expected total frequency across all modalities. |
| 4 | Contact your MAC before March 7, 2026 to confirm local frequency guidelines. CMS explicitly delegates frequency guideline development to individual MACs based on their own data. The national NCD sets the framework; your MAC sets the specific thresholds. If you haven't reviewed your MAC's published pacemaker monitoring guidelines recently, do it now — they may have updated in response to this modification. |
| 5 | Flag any claims still tied to mercury-zinc battery pacemakers for separate handling. These are rare, but they exist. If your practice or facility has any patients still on mercury-zinc units, apply the 1980 guidelines — not the current NCD 160 framework — until those units are replaced. |
| 6 | When monitoring frequency exceeds typical guidelines, build the clinical justification into the chart before billing. The physician's rationale for above-guideline monitoring frequency needs to be in the documentation, not constructed after a claim denial. If you're not sure whether your documentation standards are sufficient for your MAC, loop in your compliance officer before the March 7 effective date. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Cardiac Pacemaker Evaluation Under NCD 160
NCD 160 as published does not list specific CPT, HCPCS, or ICD-10 codes. This is worth calling out because it's operationally frustrating — the policy governs coverage for a well-defined set of services without specifying the exact billing codes.
In practice, cardiac pacemaker evaluation services are typically reported using a cluster of CPT codes for in-person pacemaker evaluation and remote (transtelephonic) monitoring. Your MAC's local coverage documentation, LCD companion articles, or billing and coding guidelines will contain the applicable codes. Do not assume NCD 160's silence on codes means anything goes — your MAC will have specific code-to-service mapping, and claims submitted under incorrect codes will deny.
Action: Pull your MAC's billing and coding article associated with pacemaker evaluation services. Cross-reference it against NCD 160 to confirm which codes are payable under this NCD versus LCD-level authority. If your MAC has not published updated guidance aligned with the March 7, 2026 modification, call your MAC's provider services line and document the conversation.
Because no codes are specified in this policy document, no code tables are included here. Publishing fabricated codes would create more billing risk than the table would prevent.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.